$SPTX News

Is Seaport Therapeutics (SPTX) Overvalued Based On Book Value?

Seaport Therapeutics (SPTX) Looks Cheap After Its Cash Runway Narrative Took Center Stage

Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgoTM in Patients with Generalized Anxiety Disorder and Sleep Disturbance

Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46

Seaport Therapeutics to Participate in September Investor Conferences

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint

Jones Trading Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $32

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) Estimate

HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50